Cargando…

Homologous recombination proficiency in ovarian and breast cancer patients

Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) poly...

Descripción completa

Detalles Bibliográficos
Autores principales: Creeden, Justin Fortune, Nanavaty, Nisha S., Einloth, Katelyn R., Gillman, Cassidy E., Stanbery, Laura, Hamouda, Danae M., Dworkin, Lance, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555001/
https://www.ncbi.nlm.nih.gov/pubmed/34711195
http://dx.doi.org/10.1186/s12885-021-08863-9
_version_ 1784591892762066944
author Creeden, Justin Fortune
Nanavaty, Nisha S.
Einloth, Katelyn R.
Gillman, Cassidy E.
Stanbery, Laura
Hamouda, Danae M.
Dworkin, Lance
Nemunaitis, John
author_facet Creeden, Justin Fortune
Nanavaty, Nisha S.
Einloth, Katelyn R.
Gillman, Cassidy E.
Stanbery, Laura
Hamouda, Danae M.
Dworkin, Lance
Nemunaitis, John
author_sort Creeden, Justin Fortune
collection PubMed
description Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) polymerase inhibitors (PARPi). However, response is limited in patients who are not HRD, highlighting the need for reliable and robust HRD testing. This manuscript will review BRCA1/2 function and homologous recombination proficiency in respect to breast and ovarian cancer. The current standard testing methods for HRD will be discussed as well as trials leading to approval of PARPi’s. Finally, standard of care treatment and synthetic lethality will be reviewed.
format Online
Article
Text
id pubmed-8555001
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85550012021-10-29 Homologous recombination proficiency in ovarian and breast cancer patients Creeden, Justin Fortune Nanavaty, Nisha S. Einloth, Katelyn R. Gillman, Cassidy E. Stanbery, Laura Hamouda, Danae M. Dworkin, Lance Nemunaitis, John BMC Cancer Review Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) polymerase inhibitors (PARPi). However, response is limited in patients who are not HRD, highlighting the need for reliable and robust HRD testing. This manuscript will review BRCA1/2 function and homologous recombination proficiency in respect to breast and ovarian cancer. The current standard testing methods for HRD will be discussed as well as trials leading to approval of PARPi’s. Finally, standard of care treatment and synthetic lethality will be reviewed. BioMed Central 2021-10-28 /pmc/articles/PMC8555001/ /pubmed/34711195 http://dx.doi.org/10.1186/s12885-021-08863-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Creeden, Justin Fortune
Nanavaty, Nisha S.
Einloth, Katelyn R.
Gillman, Cassidy E.
Stanbery, Laura
Hamouda, Danae M.
Dworkin, Lance
Nemunaitis, John
Homologous recombination proficiency in ovarian and breast cancer patients
title Homologous recombination proficiency in ovarian and breast cancer patients
title_full Homologous recombination proficiency in ovarian and breast cancer patients
title_fullStr Homologous recombination proficiency in ovarian and breast cancer patients
title_full_unstemmed Homologous recombination proficiency in ovarian and breast cancer patients
title_short Homologous recombination proficiency in ovarian and breast cancer patients
title_sort homologous recombination proficiency in ovarian and breast cancer patients
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555001/
https://www.ncbi.nlm.nih.gov/pubmed/34711195
http://dx.doi.org/10.1186/s12885-021-08863-9
work_keys_str_mv AT creedenjustinfortune homologousrecombinationproficiencyinovarianandbreastcancerpatients
AT nanavatynishas homologousrecombinationproficiencyinovarianandbreastcancerpatients
AT einlothkatelynr homologousrecombinationproficiencyinovarianandbreastcancerpatients
AT gillmancassidye homologousrecombinationproficiencyinovarianandbreastcancerpatients
AT stanberylaura homologousrecombinationproficiencyinovarianandbreastcancerpatients
AT hamoudadanaem homologousrecombinationproficiencyinovarianandbreastcancerpatients
AT dworkinlance homologousrecombinationproficiencyinovarianandbreastcancerpatients
AT nemunaitisjohn homologousrecombinationproficiencyinovarianandbreastcancerpatients